Lumos Diagnostics Holdings Ltd will hold a webinar on June 11 to update investors on the US commercialisation of its FebriDx rapid respiratory infection test following FDA CLIA waiver clearance. The test is now used in over 100 healthcare locations across 18 US states, with around 195,000 influenza tests performed in the past year. Lumos reports strong early uptake and positive reimbursement outcomes, with over 90% of claims paid and average payments exceeding Medicare benchmarks. The company aims to expand usage ahead of the 2026/27 flu season and continue building market awareness and reimbursement pathways.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
